FDA approval boosts weight loss pill co Epitomee

Dr. Shimon Eckhouse  credit: Tomer Shalom
Dr. Shimon Eckhouse credit: Tomer Shalom

Epitomee's product expands in the stomach, giving a sense of satiety. The big challenge now will be marketing.

Epitomee Medical (TASE: EPIT), chaired by serial biomed entrepreneur Shimon Eckhouse, has announced the receipt of US Federal Drug Administration (FDA) approval for the sale of its weight management pill in the US. The pill expands in the stomach, giving a sense of satiety.

Following the report, Epitomee’s share price shot up by 152% yesterday, and is up by a further 27% so far today. The company’s market cap at yesterday’s close was NIS 232 million, still 75% below its valuation in its flotation on the Tel Aviv Stock Exchange in December 2021.

The FDA approval was fairly predictable. The real challenge will be in marketing the product (the company has yet to record sales). Epitomee was to have entered the slimming market with food giant Nestlé, but the latter withdrew from the marketing agreement between the companies at the end of 2023, which is what led to the drop in Epitomee’s share price. Nestlé said that although results of clinical trials of the pill indicated a statistically significant, and substantial, weight loss from its use, they were not sufficient for it to stand behind marketing of the product.

The background to Nestlé’s decision was significant changes that had taken place in the market for obesity prevention products since Epitomee was founded, and even since its flotation. Eli Lilly and Novo Nordisk brought weight-loss inducing drugs to the market that were much more effective than anything seen before them, and more effective than Epitomee’s pill.

In Epitomee’s trial, 27% of patients lost at least 10% of their body weight, and more than 10% lost at least 15%. Eli Lilly’s drug, at high dosage, led to a weight loss of 20% or more for over half of the participants in its trial.

Epitomee has said in the past that its product is aimed at people with a low to medium degree of obesity, and those who fear the side effects of weight-loss drugs. Besides this, Epitomee CEO Dan Hashimshony stressed, talking to "Globes", that Epitomee’s pill is swallowed, whereas other treatments are administered by injection.

"Our intention now is to sign a number of agreements with distributors," Hashimshony said. "In the US, we shall work with a single distributor for each state, and in Europe with strong local distributors in each country, even if they are not well known internationally. The agreements will be classic distribution agreements, and we will announce them gradually from today until the product launch in the third quarter of 2025, and even after that."

At the end of June, Epitomee had liquid balances of $29 million, after accumulating losses of $65 million since it was founded. In the first half of this year, the company used $4.3 million for its regular operations, and, according to Hashimshony, it has sufficient cash to complete its production facility and to launch the product.

Published by Globes, Israel business news - en.globes.co.il - on September 16, 2024.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2024.

Dr. Shimon Eckhouse  credit: Tomer Shalom
Dr. Shimon Eckhouse credit: Tomer Shalom
groundcover founders credit: Yossi Yarom Israeli observability co groundcover raises $35m

groundcover has developed a “Bring Your Own Cloud” (BYOC) observability solution, redefining the architecture of a modern observability platform.

Tel Aviv Stock Exchange credit: Shutterstock MagioreStock Foreign investment in TASE hits five-year high

Foreign investors have been flocking to the Tel Aviv Stock Exchange in recent weeks, the TASE research department tells "Globes."

Elbit Systems tank turret systems credit: Elbit Systems Elbit Systems wins $100m tank turret systems deal

The Israel defense electronics company will supply its advanced UT30 MK2 unmanned turret systems to General Dynamics European Land Systems (GDELS) to be supplied to a NATO European country.

Tomer Weingarten Photo: PR Trump targets SentinelOne exec in act of revenge

The US administration has suspended the security clearance of the company's chef intelligence and public policy officer Chris Krebs and everyone associated with him.

Tel Aviv Stock Exchange share prices rising credit: Tali Bogdanovsky TASE opens sharply higher after Trump U-turn on tariffs

The pause is being interpreted as a climb down after US President Donald Trump admitted he had made the move to calm the markets.

Ashot Ashkelon credit: Ministry of Defense Up 250%, Ashot Ashkelon wins another Defense Ministry order

The Israeli defense company's share price has risen 250% in the past three years since FIMI Opportunity Funds acquired control.

Liad Agmon credit: Eyal Izhar Insight Partners Liad Agmon steps down as managing partner

Serial entrepreneur Agmon has served as a partner at Insight Partners Israel alongside Daniel Aronovitz who set up the Israel office.

Shekels credit: Shutterstock Vladerina32 Shekel slide resumes amid escalating tariff war

The Bank of Israel is not expected to intervene in the forex market despite the sharp depreciation of the shekel.

Nir Zuk credit: Inbal Marmari Palo Alto Networks mulls buying AI security co for $700m

Sources inform "Globes" that on Palo Alto's radar is Protect AI.

President Donald Trump hosts Prime Minister Benjamin Netanyahu credit: Reuters Kevin Mohatt Israeli officials confident on US tariff concessions

Senior Israeli figures believe that concessions could be tied to progress on strategic regional political issues that are important to President Trump.

Phoenix Investment House CEO Avner Hadad  credit: Tommy Harpaz "The market has priced in all the bad things"

Phoenix Investment House CEO Avner Hadad says US markets could continue to fall, but that we are close to interesting territory for patient investors.

Tel Aviv credit: Shutterstock Tel Aviv slips in World's Wealthiest Cities ranking

Tel Aviv's position as one of the world's wealthiest cities took a big knock over the past year as it slipped from 42nd to 48th in investment advisors Henley & Co.'s "World's Wealthiest Cities" Top 50 ranking.

Leviathan platform  credit: Albatross C'ttee seen recommending no cut in gas exports

The Dayan committee on the future of the gas sector estimates that Israel's natural gas reserves will run out in 2045.

Accountant General Yali Rothenberg credit: Rafi Kutz Israel's fiscal deficit continues to narrow

The deficit narrowed in the twelve months to the end of March 2025, for the sixth consecutive month, Ministry of Finance accountant general Yali Rothenberg reported today.

Arkia credit: Arkia Arkia cuts Tel Aviv - New York April fares

Arkia has cut fares at the last minute, a time when prices usually soar even higher, according to the pricing method used in the industry.

Bank of Israel Governor Prof. Amir Yaron credit: Dani Shem Tov Knesset Spokesperson BoI Governor: US tariffs could push up inflation in Israel

Prof. Amir Yaron tells "Globes" that there is a risk that the new tariffs will cause inflation to rise in the US, with a knock-on effect for Israel.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018